Cellebrite DI Ltd (NAS:CLBT)
$ 16.21 -0.29 (-1.79%) Market Cap: 4.04 Bil Enterprise Value: 3.64 Bil PE Ratio: 57.91 PB Ratio: 7.91 GF Score: 83/100

Q4 2024 Cellebrite DI Ltd Earnings Call Transcript

Feb 13, 2025 / 01:30PM GMT
Release Date Price: $21.7 (-12.92%)

Key Points

Positve
  • Cellebrite DI Ltd (CLBT) exceeded its original revenue and adjusted EBITDA targets for 2024, delivering at the higher end of ARR expectations.
  • The company achieved a Rule of 50 performance with 25% ARR growth and 25% adjusted EBITDA margins.
  • Cellebrite DI Ltd (CLBT) generated $122 million in free cash flow in 2024, showcasing strong cash generation.
  • The company reported significant growth in its Guardian and Pathfinder solutions, with Guardian ARR generating triple-digit percentage growth year-over-year.
  • Cellebrite DI Ltd (CLBT) achieved FedRAMP ready status, enhancing its potential to expand within the US federal sector.
Negative
  • The CEO search is ongoing, with no specific timeline for the appointment of a new leader.
  • There are modest headwinds due to geopolitical changes and regime disruptions in the US and Europe.
  • The company faces challenges in expanding its customer base in certain countries, impacting growth retention rates.
  • Cellebrite DI Ltd (CLBT) anticipates a modest impact on Q1 2025 results due to decisions to exit certain countries.
  • The magnitude of the EBITDA beat in Q4 2024 was lower than in previous quarters, with guidance for Q1 2025 in line with expectations.
Operator

Welcome to the Cellebrite fourth-quarter and full-year 2024 financial results conference call. (Operator Instructions)

I would now like to turn the call over to your first speaker today, Mr. Andrew Kramer. Mr. Kramer, the floor is yours.

Andrew Kramer
Cellebrite DI Ltd - Vice President, Investor Relations

Thank you, Jim, and, welcome, everybody to Cellebrite's fourth-quarter and full-year 2024 financial results call. I'm joined today at our headquarters just outside of Tel Aviv by our primary speakers: Tom Hogan, Cellebrite's Interim CEO; and Dana Gerner, Celebrite CFO. Ronnen Armon, our Chief Products and Technology Officer; and Marcus Jewell, our Chief Revenue Officer, will be available during the Q&A. There's a slide presentation that accompanies our prepared remarks. Please advance the slides in the webcast viewer to follow our commentary. We will call out the slide number we're referring to in our remarks. The call is being recorded and a replay of the recording will be made available on our website shortly after the call along with the

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot